Limitations of Use: Pathogen Reduced Cryoprecipitated Fibrinogen Complex should not be used for replacement of factor VIII.Ĭontraindicated for preparation of blood components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens.Ĭontraindicated for preparation of blood components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen. Control of uremic bleeding after other treatment modalities have failed.Second-line therapy for von Willebrand disease (vWD).Control of bleeding when recombinant and/or specific virally inactivated preparations of factor XIII or von Willebrand factor (vWF) are not available.Treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex: For residents of the United States – Learn more about the INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.Visitors in Europe, the Middle East, Africa, Asia or Latin America will find information about pathogen inactivated platelets and plasma.For residents of Canada – Specific information for pathogen reduced platelets and plasma including package inserts.For residents of the United States – Hospital blood banks and healthcare practitioners will find content related to clinical topics, implementation, and education for platelet and plasma products.For residents of the United States – Blood centers and transfusion services will find topics related to the production of INTERCEPT pathogen reduced platelet and plasma products.
0 Comments
Leave a Reply. |